Benign muscle neoplasm

Summary

Benign muscle neoplasm (MONDO:0003061) is a cancer and 34 clinical trials. Top therapeutic interventions include terlipressin, carbetocin, and dobesilic acid. A subtype of musculoskeletal system benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 34

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign muscle neoplasm
Mondo ID	MONDO:0003061
MeSH	D009214
DOID	DOID:2691, DOID:461
NCIT	C4882
UMLS	C0027086
MedGen	10236
Is cancer (heuristic)	yes

Also known as: benign muscle neoplasm · benign muscle tumor · benign muscle tumour · benign neoplasm of muscle · benign tumor of muscle · benign tumor of the muscle · benign tumour of muscle · benign tumour of the muscle · muscle neoplasm · myoma · myomatous tumor · myomatous tumour

Disease family

This is a subtype of musculoskeletal system benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm

Related subtypes (7): benign connective and soft tissue neoplasm, chondroma, ameloblastoma, benign uterine ligament neoplasm, benign neoplasm of sternum, benign neoplasm of gum, benign skeletal muscle neoplasm

Subtypes (2): benign smooth muscle neoplasm, rhabdomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dinoprostone	Phase 3 (in late-stage trials)
Epinephrine	Phase 3 (in late-stage trials)
Leuprolide	Phase 3 (in late-stage trials)
Misoprostol	Phase 3 (in late-stage trials)
Oxytocin	Phase 3 (in late-stage trials)
Ulipristal	Phase 3 (in late-stage trials)
Vasopressin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 34.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	29
PHASE4	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00528177	PHASE4	COMPLETED	Morphine vs. Oxycodone for Postoperative Pain Management
NCT00995878	PHASE4	COMPLETED	The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
NCT05806307	PHASE4	UNKNOWN	Methods Decreasing Bleeding in Open Myomectomy
NCT00562471	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation
NCT02166554	PHASE1/PHASE2	COMPLETED	The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions
NCT05170230	Not specified	RECRUITING	The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations
NCT05266534	Not specified	RECRUITING	The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets
NCT05683041	Not specified	RECRUITING	Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy
NCT06154590	Not specified	NOT_YET_RECRUITING	Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
NCT07182045	Not specified	RECRUITING	Impact of Uterine and Ovarian Vessel Occlusion on Blood Loss in High Burden Minimally Invasive Myomectomy.
NCT00351494	Not specified	UNKNOWN	Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization
NCT00891657	Not specified	COMPLETED	Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy
NCT00898170	Not specified	COMPLETED	Effect of Myoma Removal on Blood Pressure and Erythropoetin Level
NCT01032213	Not specified	COMPLETED	Effect of Magnesium Sulphate on Coagulation
NCT01412489	Not specified	COMPLETED	Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel
NCT01430208	Not specified	COMPLETED	A New Alternative to Traditional Hysteroscopy
NCT01564602	Not specified	UNKNOWN	To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy
NCT01750008	Not specified	COMPLETED	Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions
NCT01829022	Not specified	COMPLETED	Multi-center Prospective Study on E-NOTES for Myomectomy With Traction of Multidirectional Sutures
NCT01936493	Not specified	COMPLETED	Biologic Predictors of Leiomyoma Treatment Outcomes
NCT02103933	Not specified	UNKNOWN	Pilot Study to Evaluate the Knowledge and Understanding on Surgery for Patients With Hysterectomy
NCT02377492	Not specified	WITHDRAWN	Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy
NCT02737553	Not specified	COMPLETED	Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal
NCT02747550	Not specified	COMPLETED	Temporary Simultaneous Two-arterial Occlusions During Laparoscopic Myomectomy
NCT02853695	Not specified	COMPLETED	Implementation of Hysteroscopy in Flanders and the Netherlands
NCT03427671	Not specified	COMPLETED	OCL 500 Treatment of Women With Symptomatic Uterine Fibroids
NCT03880045	Not specified	UNKNOWN	Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy
NCT03880604	Not specified	UNKNOWN	Triple Tourniquets With or Without Tranexamic Acid for Reducing Blood Loss at Open Myomectomy
NCT03972917	Not specified	COMPLETED	Observation of Long-term Effects on Endometrium and Uterine Fibroids in Women With Ulipristal Acetate Therapy
NCT04694677	Not specified	UNKNOWN	Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.
NCT04983719	Not specified	COMPLETED	Transcervical Myoma Biopsy Video
NCT05242783	Not specified	COMPLETED	The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:
NCT05918536	Not specified	UNKNOWN	Orthopedic Oncology Surgery: Navigation, Intraoperative Imaging and Virtual Reality
NCT05925153	Not specified	COMPLETED	Vision Screening Study for College Students at Nankai University

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TERLIPRESSIN	4	3
CARBETOCIN	4	2
DOBESILIC ACID	4	2
VASOPRESSIN	4	2
MISOPROSTOL	4	1
MORPHINE	4	1
OXYCODONE	4	1
OXYTOCIN	4	1
CHEMBL4589226	0	1
CHEMBL4064157	0	1
CHEMBL4303358	0	1
MISOPROSTOL ACID	-1	1